نتایج جستجو برای: braf mutation

تعداد نتایج: 295289  

2013
So Young Kang Soomin Ahn Sun-Mi Lee Ji Yun Jeong Ji-Youn Sung Young Lyun Oh Kyoung-Mee Kim

BACKGROUND BRAF mutation is an important diagnostic and prognostic marker in patients with papillary thyroid carcinoma (PTC). To be applicable in clinical laboratories with limited equipment, diverse testing methods are required to detect BRAF mutation. METHODS A shifted termination assay (STA) fragment analysis was used to detect common V600 BRAF mutations in 159 PTCs with DNAs extracted fro...

2015
Filip Janku Bart Claes Helen J. Huang Gerald S. Falchook Benoit Devogelaere Mark Kockx Isabelle Vanden Bempt Martin Reijans Aung Naing Siqing Fu Sarina A. Piha-Paul David S. Hong Veronica R. Holley Apostolia M. Tsimberidou Vanda M. Stepanek Sapna P. Patel E. Scott Kopetz Vivek Subbiah Jennifer J. Wheler Ralph G. Zinner Daniel D. Karp Rajyalakshmi Luthra Sinchita Roy-Chowdhuri Erwin Sablon Funda Meric-Bernstam Geert Maertens Razelle Kurzrock

Fast and accurate diagnostic systems are needed for further implementation of precision therapy of BRAF-mutant and other cancers. The novel IdyllaTMBRAF Mutation Test has high sensitivity and shorter turnaround times compared to other methods. We used Idylla to detect BRAF V600 mutations in archived formalin-fixed paraffin-embedded (FFPE) tumor samples and compared these results with those obta...

Journal: :International journal of oncology 2009
Makiko Kawaguchi Megumi Yanokura Kouji Banno Yusuke Kobayashi Yoshiko Kuwabara Maya Kobayashi Hiroyuki Nomura Akira Hirasawa Nobuyuki Susumu Daisuke Aoki

Point mutations of KRAS and BRAF genes are thought to be important in carcinogenesis of colon cancer. In particular, gene instability caused by decreased expression of the hMLH1 gene, a DNA mismatch repair (MMR) gene, may be linked to the activating BRAF V600E point mutation in sporadic colon cancer. However, a consensus has not been established regarding the correlation between point mutations...

2015
HIDEFUMI SASAKI MASAHIKO MAEKAWA TSUTOMU TATEMATSU KATSUHIRO OKUDA SATORU MORIYAMA MOTOKI YANO YOSHITAKA FUJII

Point mutation of the BRAF gene is a genetic event that occurs in a subset of lung adenocarcinoma cases. For example, BRAF V600E is a driver mutation that can be effectively targeted using selective BRAF and/or MEK inhibitors. The present study hypothesized that an increase in BRAF copy number may be correlated with certain clinicopathological features of lung adenocarcinoma in Japanese patient...

2013
Jieun Koh Jong Rak Choi Kyung Hwa Han Eun-Kyung Kim Jung Hyun Yoon Hee Jung Moon Jin Young Kwak

BACKGROUND The aim of this study was to evaluate the proper indication of adjunctive BRAF(V600E) mutation analysis at the time of ultrasound-guided fine-needle aspiration in the diagnosis of thyroid nodules. METHODS This study included 518 nodules in 479 patients who underwent ultrasound-guided fine-needle aspiration with BRAF(V600E) mutation. We calculated and compared the diagnostic perform...

2016
Tanja Dolinsek Lara Prosen Maja Cemazar Tjasa Potocnik Gregor Sersa

BACKGROUND The aim of the study was to explore the effectiveness of electrochemotherapy (ECT) during the treatment of melanoma patients with BRAF inhibitors. Its effectiveness was tested on BRAF mutated and non-mutated melanoma cells in vitro and in combination with BRAF inhibitors. MATERIALS AND METHODS ECT with bleomycin was performed on two human melanoma cell lines, with (SK-MEL-28) or wi...

Journal: :Neuro-oncology 2014
Angela C Hirbe Melike Pekmezci Sonika Dahiya Anthony J Apicelli Brian A Van Tine Arie Perry David H Gutmann

Malignant peripheral nerve sheath tumors (MPNSTs) are rare, but deadly, soft tissue sarcomas that occur more commonly and at a younger age in individuals affected with the neurofibromatosis type 1 (NF1) inherited cancer predisposition syndrome. Currently, the only curative treatment for MPNSTs is surgery, and treatment of advanced disease is limited to cytotoxic chemotherapy with generally litt...

2017
William Bruno Claudia Martinuzzi Virginia Andreotti Lorenza Pastorino Francesco Spagnolo Bruna Dalmasso Francesco Cabiddu Marina Gualco Alberto Ballestrero Giovanna Bianchi-Scarrà Paola Queirolo Federica Grillo Luca Mastracci Paola Ghiorzo

Finding the best technique to identify BRAF mutations with a high sensitivity and specificity is mandatory for accurate patient selection for target therapy. BRAF mutation frequency ranges from 40 to 60% depending on melanoma clinical characteristics and detection technique used.Intertumoral heterogeneity could lead to misinterpretation of BRAF mutational status; this is especially important if...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2003
Rajiv Kumar Sabrina Angelini Kamila Czene Ilari Sauroja Marjo Hahka-Kemppinen Seppo Pyrhönen Kari Hemminki

PURPOSE The RAS-RAF-mitogen-activated protein kinase pathways mediate the cellular response to growth signals. In melanocytes, BRAF is involved in cAMP-dependent growth signals. Recently, activating mutations in the BRAF gene, were reported in a large proportion of melanomas. We have studied mutations in the BRAF gene and their association with clinical parameters. EXPERIMENTAL DESIGN We anal...

2016
Shuang Wen Mei Li Zhi-Min Liu Li-Sha Liu Can Tian Xiao-Qing Shao Shen Lv

The EGFR-KRAS-BRAF-MEK-ERK (MAPK) pathway plays an important role in most cancers with close association of EGFR, KRAS or BRAF mutations with carcinogenesis and drug resistance. EGFR have been developed for molecular targeted therapy of various cancers. However, it remains to be determined whether aberration of this pathway is essential for the survival of clear cell renal cell carcinoma (CCRCC...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید